[News] Improved progression-free survival in metastatic breast cancer

Addition of lapatinib to trastuzumab plus an aromatase inhibitor significantly improves progression-free survival (PFS) in patients with metastatic breast cancer, according to new research.

Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research